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A B S T R A C T
The aim of this study was to present our diagnostic and therapeutic experience with antiphospholipide syndrome
(APS) and vascular thrombosis. Ninety-nine patients with positive antiphospholipide antibodies (aPL) and vascular
thrombosis were included in the study: forty patients, according to clinical classification criteria, had primary antiphos-
pholipide syndrome (PAPS), and fifty-nine patients had secondary antiphospholipide syndrome (SAPS). In PAPS group,
82.5% of the patients were LA-positive, 37.5% of the patients were IgG aCL-positive, 27.5% of the patients were IgM
aCL-positive, and 15% of the patients were IgG antib2GPI-positive. In SAPS group, 61% of the patients were LA-posi-
tive, 50.8% of the patients were IgG aCL-positive, and 47.5% of the patients were IgM aCL-positive. Administered ther-
apy was low molecular weight heparin (LMWH) throughout 7 days, followed by warfarin with prothrombin time main-
tained between 2.0 and 3.0 INR.
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Introduction
Antiphospholipide syndrome (APS) is characterized
by venous and/or arterial thrombosis, recurrent preg-
nancy loss and presence of antiphospholipide antibo-
dies1. Two antiphospholipide antibodies related to repeat
thrombosis episodes are anticardiolipin antibodies (aCL)
and lupus anticoagulant (LA)3. Anti-b2-glycoprotein I
(anti-b2GPI) antibodies are found in sera of many, but
not all patients with APS. Primary antiphospholipide
syndrome (PAPS) occurs in patients without clinical evi-
dence of another autoimmune disease, whereas second-
ary antiphospholipide syndrome (SAPS) occurs in associ-
ation with autoimmune or other disease2.
The most common clinical manifestation of antiphos-
pholipide syndrome is thrombosis, which can affect ves-
sels of any organ. Venous thrombosis, particularly of the
lower limb, occurs in up to 55% of patients with this syn-
drome, half of which also have pulmonary embolism3–5.
Arterial thrombosis affects the brain, causing transient
ischemic attacks (TIA) or strokes. Other anatomical sites
for arterial thrombosis are heart, eye, kidney and periph-
eral arteries3–5. Vascular occlusion may occur due to em-
bolism from central sources such as vegetations on a mi-
tral or aortic valve, which are reported in up to 4% of
patients with antiphospholipide syndrome5.
We present our diagnostic and therapeutic experience
involving patients with APS and vascular thrombosis.
Subjects and Methods
Ninety-nine patients who fulfilled Sapporo classifica-
tion criteria for APS, revised according to Sydney crite-
ria, were included in the study6,7. Forty of those patients
had PAPS, while 59 had SAPS. All patients had aPL anti-
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body level determined, and as a clinical manifestation
they had vascular thrombosis affecting one of the organs.
Lupus anticoagulant was determined with test of Dade
Behring Marburg firm using LA 1 screening reagent and
LA 2 confirming reagent, which is simplified reagent Di-
lute Russell’s Viper Venom Test (DRVVT) for lupus anti-
coagulant verification. Anticardiolipin antibodies were
determined with AutostatTMII ACA test of Hycor firm,
for every isoclass, based on enzyme-linked immunosor-
bent assay (ELISA), which is used for detection of spe-
cific antibodies against cardiolipin in human serum. An -
tib2-glycoprotein-1 antibodies were identified with ETI-
Beta-Glycoprotein I IgG kit for quantitative analysis of
IgG antibodies against b2-glycoprotein 1 in human se-
rum. Preliminary tests, prothrombin time, activated par-
tial thromboplastin time, fibrinogen and thrombin time
(DADE Behring) were used for coagulogram screening,
and platelet number was determined with Cell-Dyn-4000.
Protein C (APC resistance) was determined with ProC
Global test (DADE Behring). Factor V von Leiden muta-
tion was determined according to Bertin8, prothrombin
mutation was determined according to Poort9, and C667T
mutation MTHFR was determined according to Frosst10.
Data input and processing was done in a computer table
calculator Microsoft Excel 2003, whereas software pack-
ages SPSS 13.0 for Windows and Statistica 6.0 were used
for statistical analysis.
Results
Average age in PAPS group was 54.7±14.4, while in
SAPS group it was 57.3±13.9. Ninety-nine patients, who
fulfilled clinical classification criteria for APS were in-
cluded in the study. Forty of them had PAPS, and 59 had
SAPS. All patients had aPL antibody level determined,
and as a clinical manifestation they had vascular throm-
bosis affecting one of the organs.
Table 1 shows distribution of patients according to
gender. aPL antibody analysis showed that 82.5% of pa-
tients from PAPS group, and 61% of patients from SAPS
group were LA-positive. In SAPS group, 50.8% of the pa-
tients were aCL-positive, while in PAPS group 37.5% of
the patients were aCL-positive. Picture 1 shows share of
specific aPL antibodies in patients with APS and vascu-
lar thrombosis. Distribution analysis results for patients
with PAPS and SAPS, obtained by Kolmogorov-Smir-
nova test, lead to conclusion that analysed distributions
are not normally distributed. Since the study included
relatively small number of patients, distribution normal-
ity analysis needed to be done with Mann-Whitney test,
which is a nonparametric test. On the significance level
p<0.05, it is accepted as possible the hypothesis that be-
tween patients with primary antiphospholipide syndro-
me (PAPS) and patients with secondary antiphospho-
lipide syndrome (SAPS) exists significant difference in
b2-GPI IgG and IgA aCL values (Table 2). In order to ex-
amine connection that exists between analysed variables
(LA, b2-GP1 IgG, IgG aCL, IgM aCL and IgA aCL), tables
3 and 4 show Spearman’s correlation rang coefficients
and belonging p-values obtained by testing significance
of the hypothesis. Based on obtained results, it can be
concluded that statistically significant correlation exists
only between IgG aCL and IgM aCL variables, in both
(PAPS and SAPS) groups of patients.
The most often clinical manifestation of APS was
deep vein thrombosis (DVT) of lower leg, with 45% inci-
dence in PAPS group and 32.2% incidence in SAPS
group. Cerebral stroke had similar incidence, 27.5% in
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TABLE 1
DISTRIBUTION OF PATIENTS WITH PRIMARY
ANTIPHOSPHOLIPID SYNDROME (PAPS) AND PATIENTS













Male 15 37.50 16 27.12
Female 25 62.50 43 72.88
Total 40 100.00 59 100.00
TABLE 2
RESULTS OF DIFFERENCE TEST FOR ANALYSED VARIABLE
VALUES IN PATIENTS WITH PRIMARY ANTIPHOSPHOLIPIDE
SYNDROME (PAPS) AND PATIENTS WITH SECONDARY







b2-GP1 IgG –3.774 0.000
IgG aCL –1.130 0.258
IgM aCL –1.348 0.178
IgA aCL –3.363 0.001
LA – lupus anticoagulant, aCL – anticardiolipin antibody,
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LA – lupus anticoagulant, aCL – anticardiolipin antibody,
Ig – immunoglobuline antib2-GP1 IgG – antib2glycoprotein1
PAPS group, and 30.5% in SAPS group. Myocardial in-
farction (MI) had greater incidence in SAPS group with
22%, than in PAPS group with 12.4%. Peripheral arteries
were affected almost the same in both groups of patients,
10% in PAPS group and 11.7% in SAPS group. Peripheral
veins were least affected, with 5% incidence in PAPS
group, and 3.4% incidence in SAPS group.
Discussion
From clinical point of view, it can be said that APS is a
subject of many medical specialities. Given time, the syn-
drome has become described in detail. At first in case re-
views, and then based on randomised controlled clinical
trials. Treatment approach for this syndrome, interpre-
tation of laboratory results, which are often contradic-
tory, and connecting them with clinical manifestations
present today’s great challenge for clinical doctors.
One clinical and one laboratory criterion is necessary
to make a diagnosis of APS 1. The most often clinical
manifestation of APS is vascular thrombosis, arterial or
venous. Cerebral stroke and transient ischemic attack
(TIA) are the most often presentations of arterial throm-
bosis, and recurrent cerebral strokes can cause ischemic
dementia. Large blood vessels can also be affected in this
syndrome, including aorta, causing aortal occlusion. Af-
fection of peripheral blood vessels is variable and any ar-
tery can be affected, what causes ischemy of an end
organ11.
Prospective studies support a theory that antiphos-
pholipid antibodies can be a risk factor for coronary ar-
tery disease and myocardial infarction, especially in young
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TABLE 3
SPERMANS’s CORRELATION RANG COEFFICIENTS FOR VARIABLES RELATED TO PATIENTS WITH PRIMARY ANTIPHOSPHOLIPID
SYNDROME (PAPS) AND CORRESPONDING p-VALUES OBTAINED BY TESTING HYPOTHESIS OF THEIR SIGNIFICANCE
LA b2-GP1 IgG IgG aCL IgM aCL IgA aCL
LA 1.000
0.275 –0.224 –0.068 0.170
0.086 0.165 0.676 0.294
b2-GP1 IgG 0.275 1.000 –0.241 0.012 –0.060
0.086 0.135 0.942 0.712
IgG aCL –0.224 –0.241 1.000 0.485 –0.041





0.676 0.942 0.002 0.188
IgA aCL 0.170 –0.060 –0.041 0.212 1.000
0.294 0.712 0.803 0.188
LA – lupus anticoagulant, aCL – anticardiolipin antibody, Ig – immunoglobuline, antib2-GP1 IgG – antib2glycoprotein1
TABLE 4
SPERMANS’s CORRELATION RANG COEFFICIENTS FOR VARIABLES RELATED TO PATIENTS WITH SECONDARY ANTIPHOSPHO-
LIPID SYNDROME (SAPS) AND CORRESPONDING p-VALUES OBTAINED BY TESTING HYPOTHESIS OF THEIR SIGNIFICANCE
LA b2-GP1 IgG IgG aCL IgM aCL IgA aCL
LA 1.000
0.130 –0.106 –0.022 0.025
0.327 0.423 0.866 0.848
b2-GP1 IgG 0.130 1.000 –0.017 0.001 0.188
0.327 0.899 0.994 0.153
IgG aCL –0.106 –0.017 1.000 0.576 0.167
0.423 0.899 0.000 0.207
IgM aCL –0.022 0.001 0.576 1.000 0.203
0.866 0.994 0.000 0.124
IgA aCL 0.025 0.188 0.167 0.203 1.000
0.848 0.153 0.207 0.124
LA – lupus anticoagulant, aCL – anticardiolipin antibody, Ig – immunoglobuline, antib2-GP1 IgG – antib2glycoprotein1
and middle-aged people12–14, and can present a risk for
arteriosclerosis15, and for occlusion of by-pass venous
graft16. One study reported increased IgM aCL levels in
men with coronary artery disease treated with percuta-
neous transluminal coronary angioplasty that resteno-
sed17. Manifestation of valvular disease, the most com-
mon form of aPL-related cardiac involvement, may be
seen in both primary and secondary APS patients. Spe-
cific findings range from valvular thickening to nodular
excrescences (Liebman-Sacks), mitral and aortic regurgi-
tation, and severe distortion and disfunction 18. Deep
vein thrombosis (DVT), often accompanied by pulmo-
nary embolism (PE), is the most common manifestation
of APS overall11. Venous distributions may include also
ophthalmic veins, renal or splenic veins, hepatic veins,
portal, mesenteric, adrenal veins19.
Reason for such widespread thrombosis occurrence
that can affect any body organ lies in antiphospholipid
antibody (aPL) patofisiology. Autoimmune aPL present
nothing more than autoantibodies against phospholipi-
de-binding proteins. B2GPI is the most important among
numerous potentially relevant phospholipide-binding
proteins, including prothrombin, protein C, S and Anne-
xin V. Binding with phospholipide-binding proteins, they
interfere with coagulation cascade, activating endothe-
lial cells, causing growth factor expression on monocytes,
and in that way causing thrombosis20–22.
LA and aCL antiphospholipide antibodies are the
most common in results of other authors, as well as ours.
Risk for thrombosis in aPL-positive patients is best in-
vestigated in group of patients with SLE, where 12–30%
of patients were aCL-positive23,24, and 15–34% of them
were LA-positive24,25, while 38% of patients were positive
to both aPL antibodies26. Around 50% of patients with
SLE have a history of arterial or venous thrombosis27,28.
Recurrent episodes tend to mimic the original vascular
event, with venous thrombosis following venous occlu-
sion and arterial thrombosis following arterial occlusion,
although there are exceptions when patients occasionally
develop both venous and arterial disease26. But occur-
rence of aPL in patients that do not have SLE or other
autoimmune disease or malignancy, also carries a risk of
vascular thrombosis. Besides traditional risks for throm-
bosis, such as pregnancy, surgery, long term immobilisa-
tion, LA occurrence presents up to 10 times higher risk
for thrombosis, IgG class of aCL presents 3 times higher
risk, and both antibodies together carry cumulative risk29.
When such patients develop vascular thrombosis, they
should be monitored for the rest of their life. Standard
treatment presents heparin or LMWH, followed by war-
farin, with prothrombin time maintained between 2.0
and 3.0 INR for venous thrombosis, while for recurrent
and arterial thrombosis it is advisable for INR to range
between 3.0 and 4.0, with addition of low dose aspirin
(LDA)30. Warfarin therapy does not have to last several
years for all patients. Given time, aPL level decreases or
disappears entirely, suggesting that warfarin therapy
should be cancelled. But before that, other prothrom-
botic factors, such as smoking, oral contraceptives and
congenital risk factors, should be excluded31. Asymptom-
atic, persistently aPL-positive individuals do not benefit
from low-dose aspirin for primary thrombosis prophy-
laxis, have a low overall annual incidence rate of acute
thrombosis, and develop vascular events when additional
thrombosis risk factors are present32.
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ANTIFOSFOLIPIDNI SINDROM KAO UZROK VASKULARNIH TROMBOZA
S A @ E T A K
Cilj nam je bio pokazati na{a iskustva u dijagnosticiranju i lije~enju vaskularnih tromboza u sklopu antifosfolipid-
nog sindroma (APS). 99 pacijenata s pozitivnim antifosofilipidnim antitijelima (aPL) i vaskularnim trombozama bilo je
uklju~eno u studiju: 40 pacijenata, sukladno klasifikacijskim klini~kim kriterijima imalo je primarni antifosfolipidni
sindrom (PAPS), te 59 sekundarni antifosfolipidni sindrom (SAPS). Svim pacijentima je odre|en profil protutijela. U
grupi s PAPS 82,5% pacijenata bilo je LA pozitivno, 37,5% IgG aCL, 27,5% IgM aCL, te 15% na IgG antib2GPI. U grupi
sa SAPS 61% bilo je pozitivno na LA, 50,8% na IgG aCL, 47,5% bilo je IgM aCL pozitivno. Na IgA aCL klasu antitijela
bilo je pozitivno 6,7% pacijenata, dok na antib2GPI u grupi sa SAPS 3,4% pacijenata. Nije na|en niti jedan pacijent
pozitivan isklju~ivo na IgA aCL, kao ni na antib2GPI, te oni nemaju klini~ki zna~aj. Kao terapija kori{ten je nisko-
molekularni heparin (LMWH) kroz 7 dana, potom nastavljeno s varfarinom uz odr`avanje protrombinskog vremena
izme|u 2,0–3,0 INR.
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